内容摘要：South Korea does not hold a second round of runoff elections. Subsequently, when there is a clear frontrunner it is common for two remaining rivals to launch a unified campaign in which one withdraws and supports the other in exchange for a high-profile role in the government.

South Korea does not hold a second round of runoff elections. Subsequently, when there is a clear frontrunner it is common for two remaining rivals to launch a unified campaign in which one withdraws and supports the other in exchange for a high-profile role in the government.

Associated Press religion coverage receives support through the AP’swith The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content.

The U.S. social safety net would be jolted if the budget bill backed by President Donald Trump and passed Thursday by the House of Representatives becomes law.It would impose work requirements for low-income adults to receive Medicaid health insurance and increase them for food assistance as well as cut funding for services like birth control to the nation’s biggest abortion provider.Supporters of the bill say the moves will save money, root out waste and encourage personal responsibility.

A preliminary estimate from the nonpartisan Congressional Budget Office said the proposals would reduce the number of people with health care by 8.6 million over a decade.The measure, which also includes tax cuts,

and could have provisions reworked again as it heads to the Senate.

Here’s a look at the potential impact.Dr. Greg Poland, who studies vaccine response at Mayo Clinic and was not involved in the new study, said he’s not convinced that a combo shot would be popular. And while flu comes in seasonal waves, COVID-19 has been spreading throughout the year, Poland said, posing challenges for how to time the shots to keep protection strong.

He’d also like to see data on how well the new shot protected people from infection and hospitalization.The findings are based on measuring antibodies in participants’ blood after 29 days, an indication of short-term disease protection.

Last week, Moderna pushed its target date for the vaccine’s approval to 2026 after the Food and Drug Administration requested a more direct measure: how much the shot lowered the risk of disease.“I agree in this case with FDA that efficacy data are important to see,” Poland said.